



USING OF HBV.SAG ELISA KIT TO DETECT HEPATITIS B INFECTION IN BLOOD DONORS IN AL-REFAIE BLOOD BANK

Mohammed Mousa Atta, Adnan Jawad Ahmed*and Duaa Yahea Talib

College of Agriculture, University of Sumer, 64005, Rifai DhiQar, Iraq.

Abstract

Hepatitis B virus infection remains a major public health problem throughout the world. Approximately, 350 million HBV carriers are chronically infected. Chronic carriers of HBV have an elevated risk of developing cirrhosis and hepatocellular carcinoma which lead to death of an estimated 0.5 to 1.2 million subjects annually. Worldwide, HBV infection is considered to be tenth leading cause of death. The principle way of transmission is through the blood and blood products, hemodialysis, shared needles among drug abusers, dental surgery, receiving blood or blood products. This study is carried out in Thi-Qar province–Al-Rifaei district – in general Al-Rifae hospital and blood bank from the period of the first of December/ 2016 to the first of March /2017. The aim of study was determination the efficacy of HBV. sAg ELISA kit to detection of HBV infection in blood donors. (100) one hundred blood samples were collected randomly divided into males and females, the ages was rated between 19-60 years old and all these blood samples tested by ELISA technique by using HBV. sAg ELISA kit. the results explained the number of infected cases were 11% (reading of samples < cut-off value (0.131)) and other 89% were negatively results (reading of samples > cut-off value (0.131)). statistically significant increasing of infection in case of male ($P>0.005$) compared with females, while there was no statistically significance of infection in case of residence and ages of blood donors.

Key words : HBV. sAg, Hepatitis B, Blood donors

Introduction

Hepatitis B virus is classified as one of Hepadnaviridea family and has a circular, partially double – stranded DNA (Lok and McMahon, 2009). Virus replication occurs in the liver; however, specific proteins and antibodies of the virus are present in the blood of infected individuals. Some blood tests have been developed to detect these proteins and antibodies (European Association for the Study of the Liver, 2012). Despite the availability of an effective vaccine against hepatitis B virus, its infection remains a major public health problem throughout the world. Approximately, 350 million HBV carriers are chronically infected (National Institute for Health and Care Excellence, 2013). Chronic carriers of HBV have an elevated risk of developing cirrhosis and hepatocellular carcinoma which lead to death of an estimated 0.5 to 1.2 million subjects annually (National Institute for Health and Care Excellence, 2013), World Health Organization, (2015). Worldwide, HBV

infection is considered to be tenth leading cause of death (Liaw *et al.*, 2012). The principle way of transmission is through the blood and blood products, hemodialysis, shared needles among drug abusers, dental surgery, receiving blood or blood products, cupping, tattooing, ear and nose piercing practices and sexual exposure to HBV can elevate the risk of transmission (Ott *et al.*, 2012 & 2015). The prevalence of HBV infection is high in the Western Pacific and South-East Asia;. However, a variable pattern has been observed in different regions of the Middle-East (Liaw *et al.*, 2012). Three areas were proposed on the basis of HBV prevalence in the world (National Institute for Health and Care Excellence 2013); Ott *et al.*, 2012 & 2015). The prevalence of Hepatitis B virus surface antigen (HB sAg) in hyper endemic, endemic and hypo endemic areas is more than 8%, 2%, to 7% and less than 2% respectively (National Institute for Health and Care Excellence, 2013; Hepatitis B Foundation). The prevalence of HBVsAg was reported to be 2-7% in Iran; therefore Iran was classified as an intermediate HB sAg positive area (Hepatitis B

*Author for correspondence : E-mail : Adnanjawad@yahoo.com

Foundation). An estimated 3% of the Iranian population were HB sAg carriers, varying between 1.32% and 6.3% in different regions of the country (Lozano *et al.*, 2010 & 2012; Hollinger *et al.*, 2001). Vaccination is considered to be the most effective way to control the spread of HBv (Sunbul, 2014). Recent studies have shown that the changing epidemiology of Hepatitis B virus infection in Iran is at least to some extent due to HBv vaccination as a national program in routine neonate care. The national expanded HBv vaccination program was implemented in 1993 and 2007 for new borns and adults, respectively (Liaw *et al.*, 2012); Lozano *et al.*, 2010 & 2012). In our country, programs such as behavioral interventions, syringe-distribution and vaccination, particularly among male prisoners, are suggested to limit the spread of the virus (Shi, 2013).

Aim of study:

Determine the efficacy of HBv. sAg ELISA kit to detect Hepatitis B infection in blood donors.

Materials and methods

(100) one hundred blood samples were collected randomly divided into males and females and all these blood samples tested by ELISA technique by using HBv.sAg ELISA kit (Plasmatic company).

Results

Table 1: Show the result of HBs Ag testing by ELISA technique

| Result | % | No. | Total | Cut-off value |
|----------|----|-----|-------|---------------|
| Negative | 89 | 89 | | |
| Positive | 11 | 11 | 100 | 0.131 |

Table 2: Explain the gender of studied group

| Gender | No. of blood donors | % |
|--------|---------------------|-----|
| Female | 15 | 15 |
| Male | 85 | 85 |
| Total | 100 | 100 |

Table 3: Show the frequency of studied group in case of ages

| Age group (years) | No. of blood donors | % |
|-------------------|---------------------|-----|
| >30 | 35 | 35 |
| 31-39 | 45 | 45 |
| <40 | 20 | 20 |
| Total | 100 | 100 |

Table 4: Show the frequency of studied group in case of social and demographical variances

| Residence | No. of blood donors | % |
|-----------|---------------------|-----|
| Urban | 45 | 45 |
| Rural | 55 | 55 |
| Total | 100 | 100 |

Table 5: Infected cases related to age group :

| Age group | Infected cases | Ratio |
|-----------|----------------|-------|
| >30 | 1 | 9.09 |
| 31-39 | 4 | 36.36 |
| <40 | 6 | 54.55 |
| Total | 11 | 100 |

Table 6: Infected cases related to gender

| Infected cases | Gender | Ratio |
|----------------|--------|-------|
| 11 | Male | 9 |
| | Female | 2 |

Statistically significant increasing ($P > 0.005$) in case of infection between males compared with females, there was no statistical significance in case of residence ($P < 0.035$) also in case of ages ($P < 0.075$) between age groups of studied blood donors.

Discussion

This immediate study was approximately agreed with many previous studies which conducted in blood donors in Thi-qar province but HBs Ag infected cases between 2003-2008 was ranged as follow (2.7%, 2.6%, 2.1%, 3.8%, 4.3%, 5.5%) and the causes of this decreasing in infected cases go back to the following vaccination programs in 1989 and entrance of detection methods to diagnose of infected cases among blood donors added to that increasing of social level before events of 2003 and absence of migration from surrounding countries to Iraq, all these causes lead to obviously decreasing in infection rates in Iraq (Chulanov *et al.*). In Palestine show decreasing infection (3.4-4.3%) because of the Palestine localized in middle epidemiological regions and iterance of diagnostic programs to HBs Ag in case of blood donors in 1989 (Chulanov *et al.*). but our study disagreed with previous study which appear the HBs Ag infected cases lower in Lebanon (0.3%), Egypt (1.18%), Oman (2.8%), Arabian Saudi (3.6%) and Germany (0.6%) (Devesa *et al.*, 2008). because of rigid healthy Lows in these countries. The viral hepatitis type B spreading in Iraq is increase especially after 2003 due to entrance of American army and refusable homo and hetero sexual activities in prisons and jails and what the army used of biological weapon added, that carelessness of healthy enlightenment and vaccination programs especially in poor forgotten Thi-Qar province because of many condition such as anarchy, healthy carelessness result from disintegration terrorism which finally lead to huge decreasing in laboratory tools and other medical instruments and nursing which responsible for blood testing added to that needing to transport large quantity of blood to areas of battle or war daily and not forget the

immigrations due to terrorism in Syria and north of Iraq, all these reasons lead to entrance of diseased persons to Iraq in general and Thi-Qar province especially. the result of study which appear increasing of HBv infection between blood donors agreed with previous studies in world in case of HBs Ag detection in Ghana (10.5%) and large proportion in case of Japan (16.2%) also, this result agreed with reported result in American united states (5%) (Cardona *et al.*, 2011). also, in this study table 4 showed significant relationship between HBv infection and age group agree with previous study in New York city which found the same result. Table 6 showed infected male more than female so that disagree with Turkish study which found females more than males because of high sexual activity in females (Pujol *et al.*, 2009). Tables 4, 5 showed no significant relationship between residence and ages with infection and this result disagree with other studies in India and Nigeria which consider age and residence important factors in prevalence of HBv spreading so that reported high ratio in younger age group because of high sexual activity (Kramvis *et al.*, 2005), while our study disagree with other studies in India and Nigeria in case of residence which appear high prevalence of infection in urban regions because of overcrowding with population density which lowered in rural areas (Blitz *et al.*, 1998). conclusion HBs Ag ELISA kit not enough to diagnose HBv infection and need to entrance of other techniques to confirmed infection.

Acknowledgement

I would like to express my sincere thanks and gratefulness and appreciation for all staff of Ministry of Health/department of laboratories, Al-Refaie hospital and Assist. Lecturer Ahmed Abbas Sahib/college of Agriculture suggesting the topics of this research, invaluable advice and comments during the course of investigation and writing of this research, endless patience, generousness and kindness, efforts and care are highly appreciated and will never be forgotten.

References

- Blitz, L., F.H. Pujol, P.D. Swenson, L. Porto, R. Atencio and M. Araujo (1998). Antigenic diversity of hepatitis B virus strains of genotype F in Amerindians and other population groups from Venezuela. *J. Clin Microbiol*, **36**: 648–51.
- Cardona, N.E., C.L. Loureiro, D.J. Garzaro, M.C. Duarte, D.M. García and M.C. Pacheco (2011). Unusual presentation of hepatitis B serological markers in an Amerindian community of Venezuela with a majority of occult cases. *Viol. J.*, **8**: 527.
- Chulanov, V., A. Neverov, I. Karandashova, V. Dolgin, G> Mikhailovskaya and E. Lebedeva (2012). Molecular epidemiology of HBV in Russia [abstract C.222]. Abstracts of the 14th International Symposium on Viral Hepatitis and Liver Disease. China, Shanghai, 2012.
- Deterding, K., I. Constantinescu, F.D. Nedelcu, J. Gervain, V. Nemecek and O. Srtunecky (2008). Prevalence of HBV genotypes in Central and Eastern Europe. *J. Med. Virol.*, **80**: 1707–11.
- Devesa, M., C.L. Loureiro, Y. Rivas, F. Monsalve, N. Cardona and M.C. Duarte (2008). Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia. *J. Med. Virol.*, **80**: 20–6.
- European Association for the Study of the Liver (2012). EASL clinical practice guidelines: management of chronic hepatitis B virus infection. *J. Hepatol*, **57**: 167–85.
- Hepatitis B. Foundation. Hepatitis B Foundation [Internet]. Doylestown, PA. Available from: <http://www.hepb.org/>.
- Hollinger, F. and T. Liang (2001). Hepatitis B virus. In: Knipe DM, Howley PM, editors. *Fields' virology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. 2971–3036.
- Kramvis, A., M. Kew and G. François (2005). Hepatitis B virus genotypes. *Vaccine*, **23**: 2409–23. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Hepatol Int.*, 2012; **6**: 531–61.
- Liaw, Y.F., J.H. Kao, T. Piratvisuth, H.L.Y. Chan, R.N. Chien and C.J. Liu (2009). Chronic Hepatitis B: update. *Hepatology*, **50**: 661–2.
- Liaw, Y.F., J.H. Kao, T. Piratvisuth, H.L.Y. Chan, R.N. Chien and C.J. Liu (2012). Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Hepatol Int.*, **6**: 531–61.
- Lok, A.S.F. and B.J. McMahon (2009). Chronic Hepatitis B: update 2009. *Hepatology*, **50**: 661–2.
- Lozano, R., M. Naghavi, K. Foreman, S. Lim, K. Shibuya and V. Aboyans (2010). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. *Lancet*, **380**: 2095–128.
- National Institute for Health and Care Excellence (NICE). Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults [Internet]. London: NICE; 2013. Available from: <http://www.nice.org.uk/guidance/cg165/resources/guidancehepatitis-b-chronic-pdf>
- Ott, J.J., G.A. Stevens, J. Groeger and S.T. Wiersma (2012). Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine*; **30**: 2212–9. © World Gastroenterology Organisation, 2015 WGO Global Guideline Hepatitis B 33.
- Pujol, F.H., M.C. Navas, P. Hainaut and I. Chemin (2009). Worldwide genetic diversity of HBV genotypes and risk

- of hepatocellular carcinoma. *Cancer Lett.*, **286**: 80–8.
- Shi, W., Z. Zhang, C. Ling, W. Zheng, C. Zhu and M.J. Carr (2013). Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections. *Infect Genet Evol.*, **16**: 355–61.
- Sunbul, M. (2014). Hepatitis B virus genotypes: global distribution and clinical importance. *World J. Gastroenterol.*, **20**: 5427.
- World Health Organization. Global Alert and Response (GAR): Hepatitis [Internet]. Geneva: World Health Organization [cited 2015 Mar 31]. Available from: <http://www.who.int/csr/disease/hepatitis/en/>.